Anti-CCDC22 Antibody

CCDC22 is a recently identified coiled-coil domain-containing protein that has been shown to bind copines, which are calcium-dependent, membrane-binding proteins that may function in calcium signaling. In rat, CCDC22 has been observed to localize in multiple regions of the brain, including the prefrontal and somatosensory cortex, dentate gyrus and thalamus, and in the ipsilateral motor neurons of the spinal cord after sciatic nerve transection suggesting that it may play a role in neuronal injury response. The human CCDC22 gene has been identified as a novel candidate gene for syndromic X-linked intellectual disability (XLID) .

CCDC22 antibody was raised against an 18 amino acid synthetic peptide near the amino terminus of human CCDC22. The immunogen is located within amino acids 530 - 580 of CCDC22.

Involved in regulation of NF-kappa-B signaling. Promotes ubiquitination of I-kappa-B-kinase subunit IKBKB and its subsequent proteasomal degradation leading to NF-kappa-B activation; the function may involve association with COMMD8 and a CUL1-dependent E3 ubiquitin ligase complex. May down-regulate NF- kappa-B activity via association with COMMD1 and involving a CUL2- dependent E3 ubiquitin ligase complex. Regulates the cellular localization of COMM domain-containing proteins, such as COMMD1 and COMMD10 (PubMed:23563313) . Plays a role in copper ion homeostasis. Involved in copper-dependent ATP7A trafficking between the trans-Golgi network and vesicles in the cell periphery; the function is proposed to depend on its association within the CCC complex and cooperation with the WASH complex on early endosomes (PubMed:25355947) .

CCDC22 antibody can be stored at 4°C for three months and -20°C, stable for up to one year. Avoid repeated freeze-thaw cycles. Antibodies should not be exposed to prolonged high temperatures.